Swiss biotech pulls Neuer Markt IPO

Royalty Pharma, a Swiss biotech company which generates its revenues from licensing treatments under development, has become the latest casualty of the technology correction, after it postponed its €146m ($122.7m) IPO on the Neuer Markt.

The company, which would have been valued at up to €573m in the IPO, decided to postpone the deal indefinitely as a result of market conditions. It is one of the largest companies to pull its IPO on the Neuer Markt.

WSJ Logo
Ray Dalio Sells Last Stake in Bridgewater, the Hedge Fund That Made Him a BillionaireExternal link

Ray Dalio Sells Last Stake in Bridgewater, the Hedge Fund That Made Him a Billionaire